tiprankstipranks
Trending News
More News >

EKBAX Mutual Fund Forecast & Price Targets

See the Price Targets and Ratings of:

EKBAX Analyst Rating

Moderate Buy
102ConsensusRatings
60 Buy
42 Hold
0 Sell
Based on the consensus analyst ratings on 102 stocks held in EKBAX.
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EKBAX Analyst Price Target

Average Price Target

$14.31
Based on 102 Wall Street analysts offering 12 month price targets to WF Diversified Capital Builder Fund Class A holdings in the last 3 months. The average price target is $14.31 with a high forecast of $17.59 and a low forecast of $11.54. The average price target represents a 13.04% change from the last price of $12.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","12":"$12","14":"$14","16":"$16","18":"$18"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.591,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.311,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.538,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.54</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,12,14,16,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.55,12.93776923076923,13.325538461538462,13.713307692307692,14.101076923076924,14.488846153846154,14.876615384615386,15.264384615384616,15.652153846153848,16.039923076923078,16.427692307692308,16.81546153846154,17.20323076923077,{"y":17.591,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.55,12.685461538461539,12.820923076923078,12.956384615384616,13.091846153846154,13.227307692307694,13.362769230769231,13.49823076923077,13.633692307692307,13.769153846153847,13.904615384615385,14.040076923076924,14.175538461538462,{"y":14.311,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.55,12.472153846153846,12.394307692307693,12.316461538461539,12.238615384615386,12.160769230769231,12.082923076923077,12.005076923076924,11.92723076923077,11.849384615384615,11.771538461538462,11.693692307692308,11.615846153846155,{"y":11.538,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.08,"date":1714521600000,"info":"<div>Price: <b>$12<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.61,"date":1717372800000,"info":"<div>Price: <b>$13<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.06,"date":1719792000000,"info":"<div>Price: <b>$13<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.82,"date":1722470400000,"info":"<div>Price: <b>$13<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.8,"date":1725321600000,"info":"<div>Price: <b>$13<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.28,"date":1727740800000,"info":"<div>Price: <b>$13<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.4,"date":1730419200000,"info":"<div>Price: <b>$13<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.12,"date":1733097600000,"info":"<div>Price: <b>$14<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.7,"date":1735776000000,"info":"<div>Price: <b>$14<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.91,"date":1738540800000,"info":"<div>Price: <b>$14<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.07,"date":1740960000000,"info":"<div>Price: <b>$13<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.74,"date":1743465600000,"info":"<div>Price: <b>$13<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.55,"date":1746057600000,"info":"<div>Price: <b>$13<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$17.59Average Price Target$14.31Lowest Price Target$11.54
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

EKBAX Stocks With Highest Upside Potential

Name
Price & Change
Analyst Consensus
Analyst Price Target
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Sarepta Therapeutics Inc.
18 Buy
5 Hold
0 Sell
Strong Buy
$96.57
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Biomarin Pharmaceutical Inc.
17 Buy
5 Hold
0 Sell
Strong Buy
$97.75
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Marvell Technology Group
26 Buy
3 Hold
0 Sell
Strong Buy
$99.42
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Crane Nxt, Co.
2 Buy
1 Hold
0 Sell
Moderate Buy
$80.67
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Neurocrine Biosciences
20 Buy
1 Hold
0 Sell
Strong Buy
$160.11

EKBAX Stocks With Highest Downside Potential

Name
Price & Change
Analyst Consensus
Analyst Price Target
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Curtiss-Wright Corp
4 Buy
2 Hold
0 Sell
Moderate Buy
$377.40
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Amphenol Corporation
8 Buy
1 Hold
0 Sell
Strong Buy
$83.63
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Jabil Inc.
5 Buy
2 Hold
0 Sell
Moderate Buy
$163.71
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Cintas
5 Buy
5 Hold
3 Sell
Hold
$213.82
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Ansys Inc
1 Buy
5 Hold
1 Sell
Hold
$346.80

EKBAX Mutual Fund FAQ

What is EKBAX’s average 12-month price target, according to analysts?
Based on analyst ratings, WF Diversified Capital Builder Fund Class A’s 12-month average price target is 14.31.
    What is EKBAX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for EKBAX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is EKBAX a Buy, Sell or Hold?
        WF Diversified Capital Builder Fund Class A has a consensus rating of Moderate Buy which is based on 60 buy ratings, 42 hold ratings and 0 sell ratings.
          What is WF Diversified Capital Builder Fund Class A’s price target?
          The average price target for WF Diversified Capital Builder Fund Class A is 14.31. This is based on 102 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $17.59 ,the lowest forecast is $11.54. The average price target represents N/A Increase from the current price of N/A.
            What do analysts say about WF Diversified Capital Builder Fund Class A?
            WF Diversified Capital Builder Fund Class A’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 102 Wall Streets Analysts.
              How can I buy shares of EKBAX?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis